Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 1p21 3 Microdeletion Syndrome
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 1p21 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
1p21 3 Microdeletion Syndrome
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
1p21 3 Microdeletion Syndrome
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
1p21 3 Microdeletion Syndrome
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
1p21 3 Microdeletion Syndrome
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
1p21 3 Microdeletion Syndrome
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
1p21 3 Microdeletion Syndrome
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
1p21 3 Microdeletion Syndrome
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 1p21-3-microdeletion-syndrome-C4304578 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 1p21 3 Microdeletion Syndrome | Discriminating power |
|---|---|---|---|
| Primary problem | Cortisol deficiency with androgen and possible mineralocorticoid imbalance | Chromosomal copy-number change; clinical effects are not established in the source | High |
| Early features | May include atypical genitalia, salt-wasting crisis, or growth concerns | No specific neonatal or developmental features are established here | Moderate |
| Care pattern | Chronic endocrine condition generally requiring lifelong hormone replacement | Chronic congenital condition, but management is not defined by the supplied data | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Newborn with salt-wasting or atypical genitalia
These features fit the supplied adrenal disorder better than an undefined deletion phenotype
Moderate
Abnormal steroid testing suggests 21-hydroxylase deficiency
Cortisol pathway abnormalities support CAH pending confirmatory clinical and genetic review
High
Planning hormone replacement
An endocrine diagnosis guides glucocorticoid and, when needed, mineralocorticoid care
High
Choose 1p21 3 Microdeletion Syndrome when
A microarray identifies a 1p21.3 deletion
The copy-number result defines the genetic label rather than an adrenal diagnosis
High
Congenital features occur without adrenal crisis
Genetics may be relevant, but a specific deletion phenotype is not established here
Low
Counseling after a copy-number result
A genetics clinician should interpret incomplete phenotype and severity data
Moderate
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 1p21 3 Microdeletion Syndrome | Interpretation |
|---|---|---|---|
| Steroid profile | May show cortisol deficiency and elevated 17-hydroxyprogesterone; no cutoff is supplied | No characteristic steroid abnormality is established | An abnormal result suggests an adrenal disorder, not the microdeletion |
| Serum electrolytes | Salt-wasting may involve low sodium and high potassium | No characteristic electrolyte pattern is established | Crisis results need urgent care and do not prove a chromosomal deletion |
| Genetic testing | CYP21A2-related testing may confirm CAH | Chromosomal microarray can detect 1p21.3 copy loss | These are different tests; neither result alone excludes every other condition |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Usually a chronic, treatable endocrine disorder; exact outcomes vary and are not quantified here
- Factors
- Crisis prevention, hormone balance, and monitoring of growth and puberty
1p21 3 Microdeletion Syndrome
- Outcome
- Outcome is not established from the supplied source
- Factors
- Deletion extent, involved genes, and individual findings require genetics review
Time frame: Both are described as chronic; the deletion’s precise lifelong course is unknown
Confirmed diagnosis, associated findings, treatment access, and specialist follow-up
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | Possible because of cortisol and sometimes aldosterone deficiency Not established from the supplied source Suspected crisis needs urgent treatment; do not attribute it to the deletion without evidence |
| Growth or puberty effects | Hormone excess or treatment imbalance may affect growth and puberty Growth effects are not established here Monitoring should be individualized rather than assumed to be shared |
| Developmental concerns | Not described as the core feature in the source Cannot be specified because phenotype data are missing Assess development from clinical findings, not from this comparison alone |
Patient education highlights
- HighDistinct diagnoses
These conditions have different causes and should not be treated as interchangeable.
- HighEmergency symptoms
Vomiting, weakness, dehydration, or collapse in suspected CAH needs urgent medical care.
- MediumSpecialist interpretation
Endocrine and genetics clinicians should interpret results, especially where source data are incomplete.